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SYNOPSIS 
Cancer is a disease, causes due to failure of control of growth and 
cell proliferation mechanisms. There are genetic control systems, 
regulate the balance between cell birth and death in response to growth 
signals, growth-inhibiting signals, and death signals in normal 
conditions. So, the losses of cellular regulation and corresponding 
genetic damage give rise to cancer. The ultimate goal of cancer therapy is 
to destroy cancer cells selectively without affecting the normal tissues of 
patients. But, most of the currently available anticancer agents (as well 
as radiation therapy) do not possess higher selectivity towards cancer 
cells and destroy rapidly dividing normal cells including vital tissues 
such as lympho-hematopoetic tissues, gonad, hair follicles and the lining 
epithelium of gastrointestinal tract and mouth. So, adverse side effect of 
anticancer agents limits the doses applied to cancer patients causing 
incomplete killing of cancer cells. As a result, prolong treatment is 
needed and that makes cancer cells ‘un-sensitized’ towards drugs. 
Recurrence of cancer is also an unavoidable outcome of this incomplete 
killing. 
A lot of developmental researches across the globe are going on to 
overcome these limitations with alternative approaches towards cancer 
therapy. Targeted cancer therapy using lipid-based delivery systems and 
subsequent gene delivery is an important strategy for selective cancer 
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eradication. It is also possible to reduce the drug dose using suitable 
adjuvant to overcome the adverse effect of drugs on normal cells and 
make cells sensitized towards drug molecules. 
In targeted cancer therapy, receptors are targeted using suitable 
delivery systems. Certain receptors are over-expressed in various cancers 
but not in normal cells. So, by targeting those receptors, cancer cell 
specific delivery of anticancer agents is possible. On the other hand, 
some receptors behave differently in cancer and normal cells. Those 
receptors can also be targeted to kill cancer cells selectively leaving the 
normal tissues unaffected. The development of a receptor-targeted 
delivery of anticancer agent is described in the second chapter of the 
present thesis. 
Chapter 1A: 
In This chapter, the development of synthetic bivalent inhibitors of 
N-end rule ubiquitin pathway and their in-vitro and in-vivo biological 
effect of inhibition is described. N-end rule pathway is a subset of 
ubiquitin-dependent proteolysis pathway. The N-end rule is a relation 
between the metabolic stability and fate of a protein and the identity of 
its N-terminal residue, which is called N-degron. So, the in-vivo half life 
of a protein depends upon its N-terminal residue. Proteins contain some 
specific N-terminal amino acid residues like Arg, His, Phe, Lys, Leu, Ile, 
called destabilizing residue are degraded rapidly. There are also some 
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stabilizing N-terminal residues (e.g. Met, Val) are not degraded in this 
pathway and are stable. The proteins bearing basic N-terminal residues 
(e.g. Arg, Lys, His) are type 1 substrates and the proteins bearing bulky 
hydrophobic N-terminal residues (e.g. Phe, Leu, Ile) are type 2 substrates 
of the N-end rule pathway. There is one more type of substrate, available 
in mammals, called type 3. The proteins bearing internal amino acids 
like Ala, Ser, Thr at a specific position, also recognized by N-end rule 
pathway as a type 3 substrates. The protein degradation pathway 
consists of two successive steps: (a) covalent attachment of multiple 
ubiquitin molecules to the target protein (ubiquitination) through 
recognition by a class of proteins E3, called N-recognin and (b) 
degradation of the ubiquitin-tagged protein by the 26S proteasome. N-
recognins are the E3 ubiquitin ligases involved in N-end rule pathway 
that recognize and bind to the target proteins depending on the presence 
of N-terminal destabilizing residues of proteins. Then they attach poly-
ubiquitin chains to target proteins. So, N-recognins are worthwhile to be 
targeted for selective inhibition of the N-end rule pathway of protein 
degradation. 
Recent biochemical and proteomic studies identified many 
components of the mammalian N-end rule pathway. The studies in 
various species revealed its essential role in various vital physiological 
processes, ranging from cardiovascular development and mitosis/meiosis 
to the pathogenesis of human genetic diseases. Studies indicated that 
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the increasing rates of ubiquitin conjugation via the activation of N-end 
rule pathway activation enhanced the rapid proteins degradation in 
skeletal muscles. The rapid loss of muscles accompanies many diseases 
like cancer, sepsis, diabetes etc. N-end rule pathway plays an important 
role in cardiogenesis. Recent studies showed its involvement in the 
regulation of apoptosis. So, the N-end rule inhibitor is gaining 
importance in recent days. 
The structural characterization of N-recognins reveals the presence 
of at least two spatially proximal binding sites: type 1 site binds to basic 
N-terminal residues (e.g. Arg, Lys, His) and the type 2 site binds to bulky 
hydrophobic N-terminal residues (e.g. Phe, Leu, Trp, Ile). RF-C11 was 
synthesized by our group as one of the model compounds, L1L2-Cn, 
which are composed of three replaceable components: ligand (L1L2), 
linker (Cn), and core (lysine). In RF-C11, two C11 hydrocarbon chains, 
attached with core lysine, were conjugated to the type-1 substrate Arg (R) 
and the type-2 substrate Phe (F). If the off-target interaction of the linker 
and ligand with themselves and other cellular macromolecules is ignored, 
then the N-end rule inhibitory effect of RF-C11 hetero-bivalent inhibitor 
can be mainly featured to the linker length.  
To this end a series of molecules (RF-Cn) have been synthesized 
with varying chain length. Arg and Phe were conjugated to hydrocarbon 
linkers (n= 1, 2, 4, 7, 8, and 14), which in turn were linked to the core 
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Lys moiety by its ε- and α- amine group respectively. The carboxylic acid 
group of Lys is kept esterified to prevent further reactions. We got a 
series of compounds namely, RF-C2, RF-C3, RF-C5, RF-C8, RF-C9, and 
RF-C15 respectively. Two homo-bivalent inhibitors, RR-C5 (where, n=4, 
& bearing Arg at its both termini) and FF-C5 (where, n=4, & bearing Phe 
at its both termini), were also synthesized to observe the effects of homo-
bivalent interactions compared to hetero-bivalent interaction. A 
structural control, GV-C5, bearing two stabilizing amino acid residues 
Gly and Val at its termini, had been synthesized to look at the non-
selective interaction with N-recognins. The structures of the synthesized 
hetero-bivalent inhibitor molecules are represented in scheme 1. 
 
 
 
 
 
 
 
Scheme 1: Structures of synthesized bivalent inhibitors. 
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All the synthesized bivalent inhibitors were examined for their 
efficiency in inhibiting the N-end rule pathway mediated protein 
degradation in vitro and in vivo. The structure-activity relationship study 
was done with synthesized RF-Cn molecules in a time- and dose-
dependent manner. Among the inhibitors the maximum protein 
degradation inhibiting activity was observed with RF-C5 and RF-C9 both 
in type 1 and type 2 models for longer time. All the hetero-bivalent 
inhibitors were more effective in inhibiting the degradation of both type 1 
and type 2 N-end rule substrates than that of di-peptides bearing N-
terminal destabilizing residues, used as control molecule. As RF-C5 was 
one of the most efficient inhibitor, corresponding homo-bivalent control 
molecules RR-C5 and FF-C5 were synthesized.  RR-C5 showed very 
limited inhibition of degradation of type 1 substrates only, though at 
higher concentrations in comparison to RF-C5. Similarly, FF-C5, at 
higher concentrations, inhibited the degradation of type 2 substrates 
only. Structural control molecule GV-C5 showed no inhibition of 
degradation of both type 1 & type 2 substrates.   
Chapter 1B: 
 This chapter describes the development of hetero-bivalent N-
end rule pathway inhibitor as an adjuvant for drug molecules in various 
cancer cells. As discussed earlier, N-end rule pathway has a great 
importance in animal physiology. It had been shown that N-end rule 
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regulates apoptosis, a process of programmed cell death in multicellular 
organism. Multiple apoptosis and cell cycle-related factors are 
ubiquitinated by N-end rule pathway. Caspases cleave various target 
proteins to give protein fragments of destabilizing N-degron residues, 
which are recognized and degraded via N-end rule pathway.  
On the other hand, the destructive potential of caspases is 
restrained by Inhibitors of Apoptosis Proteins (IAPs). IAPs exhibit self-Ub 
ligase activity which is important for its inhibitor of apoptosis function as 
it complexes with equimolar amount of caspases for the ubiquitination 
and degradation. During apoptosis IAPs are cut by activated caspases 
and the fragmented parts of IAPs are degraded through N-end rule 
pathway. Incidentally, XIAP, the mammalian counterpart of IAP, is 
fragmented into a Type 3 N-end rule substrate by caspases. However, our 
hypothesis was to decipher this pathway’s role in functional regulation of 
XIAP in cancer. 
 In cancer, XIAP has another critical role to play. PTEN, which 
regulates Akt/PKB kinase pathway, is ubiquitinated and degraded by 
XIAP. This Akt/PKB kinase pathway regulates phosphorylation of Mdm2 
and hence, regulates the recognition and ubiquitination of nuclear wild 
type p53 present in 50% of all cancer cells.     
Additionally, N-end rule pathway also maintains the chromosomal 
stability by degrading a cohesin complex sub-unit (SCC1/RAD21, SCC1 
counterpart in mammals) cleaved by separase at the metaphase to 
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anaphase transition. This also clues to the fact that antagonizing N-end 
rule pathway might lead to chromosomal instability in normal 
functioning cells. This chromosomal instability makes cells ‘sensitized’ 
towards drug molecules. 
The present study was designed to see the sensitizing effect of our 
novel, synthetic hetero-bivalent N-end rule pathway inhibitor RF-C11, 
previously designed and characterized in our lab. RF-C11 was co-treated 
with existing anticancer drugs on cells. We observed that the co-
treatment significantly enhanced drug sensitivity in cancer cells through 
simultaneous reduction of XIAP and in vivo stabilization of RAD21. But, 
there was no such effect on normal cells. Wild type p53 up-regulation 
was observed due to the down-regulation of XIAP via N-end rule pathway. 
Co-treatment group induced apoptosis in cancer cells and also cell cycle 
arrest at G2/M phase. So, altogether we got significant cytotoxicity effect 
of co-treatment in cancer cells but not in normal cells. These data have 
given new insights into how N-end rule pathway may be manipulated for 
the development of anticancer therapeutics.  
Chapter 2: 
This chapter of present thesis consists of the targeted liposomal 
delivery of micro-RNA precursor in plasmid form into cancer cells. Micro-
RNAs (miRNAs) are 19-24 nucleotide long non-coding RNAs, regulate 
gene expression by binding with mRNAs imperfectly or perfectly. miRNAs 
are encoded by the specific genes and sometimes derived from the 
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introns of pre-mRNAs. If miRNAs have nearly perfect complementarities 
to mRNA target sequences positioned in either coding or 3’ untranslated 
(3’UTR) regions (in plants), then the perfect base pairing triggers mRNA 
degradation through a mechanism similar to that of RNA interference 
(RNAi). But, in animals, with very few exceptions, miRNAs do not posses 
perfect base pairing like plants. In animals, they regulate gene 
expression by imperfect base pairing to the 3’ UTR of target mRNAs and 
inhibit protein synthesis or causing mRNA degradation. miRNAs have 
important role in physiological processes, as they regulate gene 
expression.  
Here, we delivered artificial miRNA (amiR) against one of the most 
abundant and ubiquitously express cellular chaperon protein Hsp90 
(amiR-Hsp90) in the form of plasmid. Hsp90 as chaperon maintains the 
structural integrity of many of its client proteins, which are involve in 
cellular growth, differentiation and apoptotic pathways. So, by targeting 
one protein expression it could be possible to target many other proteins 
involving in various cellular processes. Here, we used amiR-Hsp90 
plasmid in-stead of small molecules which have some limitations like 
non-specific toxicity, bio-availibility, and solubility.  
 Cationic lipid-based delivery system, liposome, is a good choice to 
overcome the limitations created by small molecules. Dexamethasone 
associated lipoplex (liposome plasmid complex, DX) was used here as 
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delivery system, which acts via glucocorticoid receptor (GR). GR is also a 
client protein of Hsp90 and it maintains the structural integrity of 
ligand-binding domain (LBD) of GR. The LBD of GR allows only two 
molecules of synthetic GR-ligand, dexamethasone (Dex), as it is tightly 
regulated by Hsp90 in normal cells. Our group recently discovered that 
DX could gain GR-mediated nuclear access only in cancer cells and 
eventually expresses the delivered gene, though the size of DX is many 
folds bigger than that of LBD of GR. Similar GR-mediated nuclear 
delivery of DX lipoplex could not be observed in normal cells unless 
Hsp90 was inhibited. This proved that functional activity of Hsp90 must 
be somewhat compromised in cancer cells. GR helps nuclear delivery DX 
only in cancer cells using the compromised functional activity of Hsp90, 
though the cellular uptake of DX was same for both cancer and normal 
cells. This encouraged us to use this delivery system (DX) to deliver 
amiR-Hsp90 plasmid in cancer cells. The DX-mediated delivery to cancer 
cells & selective processing of plasmid in those cells is expected to be 
more effective in comparison to that in normal cells.  
Artificial miRNAs (amiRs), in plasmid form, utilize the cellular 
machinery for expression, processing and targeting of mRNAs to repress 
their protein level expression. Artificial miRNA in plasmid form (pri-
miRNA) has to be processed in nucleus by Drosha following the 
processing in cytoplasm by Dicer to form mature miRNA. Therefore, this 
targeted delivery system (DX) has been used to deliver genetic cargo like 
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amiR-Hsp90 into nucleus of cancer cells to get the repressor effect of 
miRNA against Hsp90 protein. 
Unlike amiRs in plasmid form, mature miRNAs need not to be 
processed from nucleus. Cytoplasmic delivery of mature miRNAs is 
enough to get their effect. As far as cytoplasmic delivery is concerned, 
our delivery system DX cannot differentiate between cancer cells and 
normal cells. But DX can differentiate between cancer cells and normal 
cells as far as GR-mediated nuclear delivery of genetic cargo is 
concerned. On the basis of this important observation, we planned to use 
amiR-Hsp90 in plasmid form to target specific deliver and process it to 
down-regulate Hsp90 in cancer specific manner. 
  The plasmid bearing the artificial miRNA gene (amiR-Hsp90) was 
then complexed with GR-targeted cationic liposomal delivery system DX 
(DX-amiR-hsp90). The anticancer efficacy of lipid/DNA complex was first 
tested in cells in vitro. The down-regulation of Hsp90 at the mRNA level 
was observed by RT-PCR analysis. The comparison of the levels of Hsp90 
and its cancer implicated client proteins was accomplished by western 
blot analysis. We observed down-regulation of Akt1 and corresponding 
phospho-Akts, anti-apoptotic protein bcl-2 and VEGF-R2 & up-
regulation of apoptotic protein p53 and Caspases. Overall western blot 
data indicated the induction of apoptosis and repression of cells 
proliferation through the down-regulation of cancer related client 
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proteins of Hsp90. The in-vivo studies in two different tumor models 
(mouse melanoma & human lung adenocarcinoma) showed significant 
tumor regression. This, to our knowledge, is the first evidence of GR-
assisted targeted gene therapy against Hsp90 for eliciting selective and 
highly efficient anticancer response. 
         
